Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362843 · ClinicalTrials.gov registry record
Protein Synthesis in the Brain of Patients With Fragile X Syndrome
A clinical trial, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 147
- Enrollment target
NCT00362843 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 147 participants.
The verdict
NCT00362843 has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 147 participants
- Enrollment target
Study Summary
Biosynthesis of proteins is essential for growth and continued maintenance of the entire neuron including axons, dendrites, and synaptic terminals, and it is clearly one of the important biochemical processes underlying adaptive changes in the nervous system. Studies in experimental animals with the quantitative autoradiographic L \[1 (14)C\]leucine method have demonstrated a number of the physiological and pathological conditions in which changes in regional rates of cerebral protein synthesis (rCPS) occur. We have recently developed the first fully quantitative method for determining rCPS with positron emission tomography (PET). The PET method was adapted from the autoradiographic L \[1 (14)C\]leucine method; it uses L \[1 (11)C\]leucine as the PET tracer, dynamic scanning, and a kinetic modeling approach for quantification. This method was validated in nonhuman primates by comparison of PET measurements with those based on established biochemical and autoradiographic techniques. The objective of the present study is to examine the degree to which changes in rCPS in human subjects can be quantified with the L \[1 (11)C\]leucine PET method. We propose three studies to be carried out sequentially. In Part I we will establish the L-\[1-(11)C\]leucine PET method in human subjects. In Part II we will measure rCPS in normal control subjects in two states: awake and under deep sedation/general anesthesia with propofol. A difference in rCPS between these two states may indicate that we can detect activity-dependent protein synthesis with the PET method. In Part III we will study subjects with fragile X syndrome. This patient group was chosen since the affected gene in fragile X syndrome codes for a protein that is thought to be a negative regulator of message translation. Thus an effect on protein synthesis may be very close to the underlying genetic abnormality in fragile X syndrome. Regionally selective increases in rCPS have been found in studies in a mouse model of
Interventions
- DRUG [15-O]water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2006-08-22 |
| Est. Completion | 2020-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362843
The ClinicalTrials.gov registry entry for NCT00362843 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [15-O]water is the first listed.
NCT00362843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00362843 about?
NCT00362843 is a clinical study titled "Protein Synthesis in the Brain of Patients With Fragile X Syndrome". Biosynthesis of proteins is essential for growth and continued maintenance of the entire neuron including axons, dendrites, and synaptic terminals, and it is clearly one of the important biochemical processes underlying adaptive changes in the nervous system. Studies in experimental animals with the...
What is the current status of trial NCT00362843?
This trial is currently completed. The enrollment target is 147 participants. The study started on 2006-08-22. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT00362843?
The interventions under investigation include: [15-O]water (DRUG).
Who is sponsoring clinical trial NCT00362843?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.